NEW YORK – With its recent licensing deal with Siemens Healthineers, Quanterix has taken a step toward the clinical market.
The agreement, under which Quanterix will give Siemens access to antibodies to the neurofilament light chain (Nf-l) protein, provides the Billerica, Massachusetts-based immunoassay firm with an opportunity to explore the clinical utility of the Nf-l marker without having to move its instrumentation into the clinical space.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.